We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$949M
AUM Growth
+$37.8M
Cap. Flow
-$30.5M
Cap. Flow %
-3.21%
Top 10 Hldgs %
31.29%
Holding
98
New
10
Increased
21
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$34M
2
ZBH icon
Zimmer Biomet
ZBH
+$18.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.6M
4
ISRG icon
Intuitive Surgical
ISRG
+$10.3M
5
PRCT icon
Procept Biorobotics
PRCT
+$9.22M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$21.9M
2
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$8.61M
3
THC icon
Tenet Healthcare
THC
+$8.54M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$8.33M
5
UNH icon
UnitedHealth
UNH
+$7.82M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Industrials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.02T
$38M 4%
+81,000
New +$34M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$11.6B
$32.9M 3.47%
380,000
+155,000
+69% +$14.6M
CI icon
3
Cigna
CI
$73.7B
$32.3M 3.4%
114,985
+30,485
+36% +$7.94M
BSX icon
4
Boston Scientific
BSX
$69.5B
$31.4M 3.31%
580,000
-20,000
-3% -$1.04M
MCK icon
5
McKesson
MCK
$100B
$30.3M 3.2%
71,000
+9,000
+15% +$3.46M
UNH icon
6
UnitedHealth
UNH
$376B
$28.8M 3.04%
60,000
-16,000
-21% -$7.82M
ABT icon
7
Abbott
ABT
$183B
$27.1M 2.86%
249,000
+64,000
+35% +$6.82M
MDT icon
8
Medtronic
MDT
$109B
$25.7M 2.71%
292,000
+57,000
+24% +$4.91M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$78.5B
$25.1M 2.65%
35,000
-500
-1% -$386K
BDX icon
10
Becton Dickinson
BDX
$45.6B
$25.1M 2.64%
95,000
-7,000
-7% -$1.78M
ELV icon
11
Elevance Health
ELV
$81.5B
$24.9M 2.62%
56,000
– –
THC icon
12
Tenet Healthcare
THC
$20.5B
$23.6M 2.49%
290,000
-120,000
-29% -$8.54M
COR icon
13
Cencora
COR
$60.6B
$22.9M 2.41%
119,000
-30,000
-20% -$5.19M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$121B
$22.3M 2.36%
63,500
-20,000
-24% -$6.74M
MRK icon
15
Merck
MRK
$322B
$21.9M 2.31%
190,000
-51,000
-21% -$5.79M
HUM icon
16
Humana
HUM
$43.7B
$20.6M 2.17%
46,000
+16,000
+53% +$8.05M
COO icon
17
Cooper Companies
COO
$14.1B
$20.2M 2.13%
211,200
-60,800
-22% -$5.7M
ABBV icon
18
AbbVie
ABBV
$443B
$20.2M 2.13%
150,000
-2,000
-1% -$293K
ZBH icon
19
Zimmer Biomet
ZBH
$18.2B
$20.1M 2.12%
+138,000
New +$18.8M
HCA icon
20
HCA Healthcare
HCA
$87.2B
$19.6M 2.06%
64,500
-19,500
-23% -$5.42M
BIIB icon
21
Biogen
BIIB
$30B
$18.4M 1.94%
64,500
+17,000
+36% +$5.06M
GILD icon
22
Gilead Sciences
GILD
$162B
$18M 1.9%
234,000
-25,000
-10% -$1.99M
JAZZ icon
23
Jazz Pharmaceuticals
JAZZ
$15.9B
$18M 1.89%
145,000
-5,000
-3% -$673K
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$17.3M 1.82%
190,000
+5,000
+3% +$431K
CVS icon
25
CVS Health
CVS
$133B
$17.1M 1.81%
248,000
+75,000
+43% +$5.34M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rhenman & Partners Asset Management held 98 positions worth $949M, up 4.1% from $911M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $30.5M in Q2 2023, closing 15 positions and reducing 41 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $8.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Eli Lilly worth $38M.

  • Rhenman & Partners Asset Management's largest Q2 2023 buy was Eli Lilly: 81,000 shares worth $38M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q2 2023, an estimated $14.6M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2023 reduction was Thermo Fisher Scientific, cutting an estimated $21.9M.
  • Rhenman & Partners Asset Management fully exited Silk Road Medical, Inc. Common Stock in Q2 2023, selling an estimated $8.61M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $949M portfolio in Q2 2023.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 15 in Q2 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 4.1% quarter-over-quarter to $949M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.